Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Starsource Multitrade Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Starsource Multitrade Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Starsource Multitrad - Revised Outcome Of Board Meeting Held On February 12, 2026
-
Starsource Multitrad - Results For The Quarter And Nine Months Ended December 31, 2025
-
Starsource Multitrad - Board Meeting Outcome for Outcome Of Board Meeting For Unaudited Financial Results For The Quarter And
-
Starsource Multitrad - Board Meeting Intimation for Considering And Approve The Un-Audited Financial Results For The Quarter
-
Starsource Multitrad has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Starsource Multitrad - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Starsource Multitrad - Declaration Of Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulation, 2015
-
Starsource Multitrad - Change In Domain Name Of Website Of The Company
-
Starsource Multitrad - Announcement under Regulation 30 (LODR)-Change in Management
-
Starsource Multitrad - Intimation Of Receipt Of No-Objection Letter For Reclassification Of Promoter(S) /Promoter Group Under
-
Starsource Multitrad - Intimation Of Receipt Of Request For Reclassification From ''Promoter Group Shareholder'' To ''P
-
Starsource Multitrad - Intimation Of Receipt Of Request For Reclassification From ''Promoter Group Shareholder'' To ''P
-
Starsource Multitrad - Intimation Of Receipt Of Request For Reclassification From ''Promoter Group Shareholder'' To ''P
-
Starsource Multitrad - Intimation Of Receipt Of Request For Reclassification From ''Promoter Group Shareholder'' To ''P
Key fundamentals
Evaluate the intrinsic value of Starsource Multitrade Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 13.1446 | 12.8024 | 11.602 | 11.5547 | 10.9947 |
| Liabilities | 13.1446 | 12.8024 | 11.602 | 11.5547 | 10.9947 |
| Equity | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Gross Profit | -0.1163 | -0.1863 | -0.2088 | -0.405 | -0.3333 |
| Net Profit | 0.3422 | 1.2003 | 0.0473 | 0.5599 | 0.25 |
| Cash From Operating Activities | -0.2824 | 0.7236 | -0.6834 | -0.3285 | 1.5484 |
| NPM(%) | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.1163 | 0.1863 | 0.2088 | 0.405 | 0.3333 |
| ROE(%) | 23.8 | 83.5 | 3.29 | 38.94 | 17.39 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Starsource Multitrade Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 731.00 | 0.32 | 43.09 | 56.50 | 301.39 | 0.69 |
| Lotus Eye Hospital and Institute Ltd | 117.30 | -4.98 | 379.06 | 205.88 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 18.22 | -2.57 | 0.00 | 427.48 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 635.80 | -0.87 | 0.00 | 194.15 | -604.77 | 0.00 |
Company Info
The Chemo Pharma Laboratories Limited has been an established Company since 1942 and has been making Pharmaceuticals and also had diversified into bulk drugs. However due to increase in competition and flow of new drugs, the Company had to dispose the business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals. 2011 -Registered office of the company has been shifted from Plot no. 5 MIDC, Kalayan -Bhiwandi Road via Kalayan Thane (Maharashtra) to 5, Kumud Apts, CHS Ltd., Karnik Road, Chikan Ghar, Kalyan Dist. Thane-421 301. 2025-Company name has changed to Starsource Multitrade Ltd. from Chemo Pharma Laboratories Ltd..
The Chemo Pharma Laboratories Limited has been an established Company since 1942 and has been making Pharmaceuticals and also had diversified into bulk drugs. However due to increase in competition and flow of new drugs, the Company had to dispose the business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals. 2011 -Registered office of the company has been shifted from Plot no. 5 MIDC, Kalayan -Bhiwandi Road via Kalayan Thane (Maharashtra) to 5, Kumud Apts, CHS Ltd., Karnik Road, Chikan Ghar, Kalyan Dist. Thane-421 301. 2025-Company name has changed to Starsource Multitrade Ltd. from Chemo Pharma Laboratories Ltd..
Read More
Parent Organisation
Starsource Multitrade Ltd.
Founded
17/08/1942
Managing Director
Mr.Ruchit Mehta
NSE Symbol
FAQ
The current price of Starsource Multitrade Ltd is
The 52-week high for Starsource Multitrade Ltd is
The market capitalization of Starsource Multitrade Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Starsource Multitrade Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Starsource Multitrade Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Starsource Multitrade Ltd shares.
The CEO of Starsource Multitrade Ltd is Mr.Ruchit Mehta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
